Literature DB >> 14534372

Atypical endometrial hyperplasia: grounds for possible misdiagnosis of endometrial adenocarcinoma.

Pedro Valenzuela1, J Miguel Sanz, Jerry Keller.   

Abstract

OBJECTIVE: The diagnoses of atypical hyperplasia and well-differentiated adenocarcinoma imply totally different approaches because of clinical and patient-oriented ramifications, especially when morphological differences are not entirely conclusive. The purpose of this study was to examine the relationship between the diagnosis of atypical hyperplasia during curettage or endometrial biopsy and the definitive histological findings from hysterectomy material. STUDY
DESIGN: 23 patients were found fit for the current study and subsequently their clinical histories were reviewed for relevant clinical data, histopathological profiling and type of therapeutic interventions.
RESULTS: Adenocarcinoma was observed in 12 (52.17%) of 23 hysterectomy cases. The hyperplasia was found in 10 (43.47%) cases, although 4 of them lacked atypia and 1 case proved to be hyperplasia-free.
CONCLUSION: Hysterectomy was prescribed as the next step in the diagnosis of atypical endometrial hyperplasia. Other wait-and-see approaches could have easily forfeited the chances of providing an adequate treatment for an operable and curable cancer in approximately half of the studied cases. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 14534372     DOI: 10.1159/000073950

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  8 in total

1.  Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia.

Authors:  Anthony B Costales; Kathleen M Schmeler; Russell Broaddus; Pamela T Soliman; Shannon N Westin; Pedro T Ramirez; Michael Frumovitz
Journal:  Gynecol Oncol       Date:  2014-10-12       Impact factor: 5.482

2.  Does Preoperative Diagnosis of Endometrial Hyperplasia Necessitate Intraoperative Frozen Section Consultation?

Authors:  Gokhan Boyraz; Derman Başaran; Mehmet C Salman; Nejat Özgül; Kunter Yüce
Journal:  Balkan Med J       Date:  2016-11-01       Impact factor: 2.021

3.  Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.

Authors:  Susan D Reed; Katherine M Newton; Rochelle L Garcia; Kimberly H Allison; Lynda F Voigt; C Diana Jordan; Meira Epplein; Elizabeth Swisher; Kristen Upson; Kelly J Ehrlich; Noel S Weiss
Journal:  Obstet Gynecol       Date:  2010-08       Impact factor: 7.661

4.  Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Authors:  James V Lacey; Mark E Sherman; Brenda B Rush; Brigitte M Ronnett; Olga B Ioffe; Máire A Duggan; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

5.  Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis.

Authors:  Michelle T Doherty; Omolara B Sanni; Helen G Coleman; Chris R Cardwell; W Glenn McCluggage; Declan Quinn; James Wylie; Úna C McMenamin
Journal:  PLoS One       Date:  2020-04-28       Impact factor: 3.240

Review 6.  Endometrial hyperplasia as a risk factor of endometrial cancer.

Authors:  Lisa K Nees; Sabine Heublein; Sahra Steinmacher; Ingolf Juhasz-Böss; Sara Brucker; Clemens B Tempfer; Markus Wallwiener
Journal:  Arch Gynecol Obstet       Date:  2022-01-10       Impact factor: 2.493

7.  Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan.

Authors:  J V Lacey; O B Ioffe; B M Ronnett; B B Rush; D A Richesson; N Chatterjee; B Langholz; A G Glass; M E Sherman
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

8.  Lymph node dissection in atypical endometrial hyperplasia.

Authors:  Salih Taşkın; Özgür Kan; Ömer Dai; Elif A Taşkın; Kazibe Koyuncu; Ayşegül Alkılıç; Mete Güngör; Fırat Ortaç
Journal:  J Turk Ger Gynecol Assoc       Date:  2017-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.